Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-((((1r)-1-(3-((e)-2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-cyclopropaneacetic Acid
2. Mk 0476
3. Mk-0476
4. Montelukast
5. Singulair
6. Sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate
1. 151767-02-1
2. Singulair
3. Montair
4. Montelukast Sodium Salt
5. Montelukast Sodium [usan]
6. Montelukast (sodium)
7. Mk-476
8. Mk-0476
9. Montelukast Na
10. Montelukast (as Sodium)
11. Montelukast Monosodium Salt
12. U1o3j18sfl
13. Chebi:6993
14. Sodium (r,e)-2-(1-(((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetate
15. 151767-02-1 (sodium)
16. Singular
17. Nsc-759107
18. Dsstox_cid_26450
19. Dsstox_rid_81624
20. Dsstox_gsid_46450
21. Cyclopropaneacetic Acid, 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-, Sodium Salt, (r-(e))-
22. Kokast
23. Mls001304727
24. Sodium (r,e)-2-(1-((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propylthio)methyl)cyclopropyl)acetate
25. Cas-151767-02-1
26. Cyclopropaneacetic Acid, 1-[[[(1r)-1-[3-[(1e)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, Sodium Salt (1:1)
27. Smr000469188
28. Sodium;2-[1-[[(1r)-1-[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetate
29. Mk 476
30. Unii-u1o3j18sfl
31. Mk 0476
32. Kipres
33. Lukasm
34. Mfcd00931431
35. Singulair (tn)
36. Cpd000469188
37. Ncgc00164568-01
38. Montelukast Sodium- Bio-x
39. Schembl9414
40. Schembl9415
41. Mls001424198
42. Sodium 1-((((r)-m-((e)-2-(7-chloro-2-quinolyl)vinyl)-alpha-(o-(1-hydroxy-1-methylethyl)phenethyl)benzyl)thio)methyl)cyclopropaneacetate
43. Chembl1200681
44. Dtxsid8046450
45. Montelukast Sodium [jan]
46. Montelukast Sodium (jp17/usp)
47. Hms2051f18
48. Hms2235h19
49. Hms3885d11
50. Montelukast Sodium [vandf]
51. Montelukast Sodium [mart.]
52. Act06295
53. Montelukast Sodium [usp-rs]
54. Montelukast Sodium [who-dd]
55. Tox21_112197
56. Mk0476
57. S4211
58. Akos015833416
59. Akos032949734
60. Tox21_112197_1
61. Am62787
62. Bcp9000959
63. Ccg-101049
64. Cs-0548
65. Ks-1087
66. Nc00299
67. Nsc 759107
68. Montelukast Monosodium Salt [mi]
69. Montelukast Sodium [orange Book]
70. Montelukast Sodium [ep Monograph]
71. Ncgc00164568-04
72. Bm164606
73. Cyclopropaneacetic Acid, 1-((((1r)-1-(3-((1e)-2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)-, Monosodium Salt
74. Hy-13315
75. Montelukast Sodium [usp Monograph]
76. M2340
77. Sw197679-2
78. 2-[1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]thio]methyl]cyclopropyl]acetate; Sodium
79. D00529
80. J-008841
81. J-522711
82. L-706631
83. Q27107384
84. 1-((((1r)-1-(3-((1e)-2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic Acid Monosodium Salt
85. 1-[[[(1r)-1-[3-[(1e)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic Acid Sodium Salt
86. 1-[[[(r)-1-[3-[2-(7-chloro-2-quinolyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-1-cyclopropaneacetic Acid Sodium Salt
87. Cyclopropaneacetic Acid,1-[[[(1r)-1-[3-[(1e)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-,sodium Salt
88. Sodium {1-[({(1r)-1-{3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetate
89. Sodium 1-((((r)-m -((e)-2-(7-chloro-2-quinolyl)vinyl)-alpha-(o-(1-hydroxy-1-methylethyl)phenethyl)benzyl)thio)methyl)cyclopropaneacetate
90. Sodium 1-((((r)-m-((e)-2-(7-chloro-2-quinolyl)vinyl)-.alpha.-(o-(1-hydroxy-1-methylethyl)phenethyl)benzyl)thio)methyl)cyclopropaneacetate
91. Sodium 1-[[[(1r)-1-[3-[(1e)-2-(7-chloroquinoline-2-yl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetate
92. Sodium 2-(1-((((r)-1-(3-((e)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)sulfanyl)methyl)cyclopropyl)acetate
93. Sodium(r,e)-2-(1-(((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetate
| Molecular Weight | 608.2 g/mol |
|---|---|
| Molecular Formula | C35H35ClNNaO3S |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 12 |
| Exact Mass | 607.1923871 g/mol |
| Monoisotopic Mass | 607.1923871 g/mol |
| Topological Polar Surface Area | 98.6 Ų |
| Heavy Atom Count | 42 |
| Formal Charge | 0 |
| Complexity | 898 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Montelukast sodium |
| PubMed Health | Montelukast (By mouth) |
| Drug Classes | Anti-Inflammatory |
| Drug Label | Montelukast sodium, the active ingredient in montelukast sodium tablets and montelukast sodium chewable tablets, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT1 receptor.Montelukast sodi... |
| Active Ingredient | Montelukast sodium |
| Dosage Form | Tablet; Granule; Tablet, chewable |
| Route | Oral |
| Strength | eq 4mg base; eq 5mg base; eq 4mg base/packet; eq 10mg base |
| Market Status | Prescription |
| Company | Vintage Pharms; Mylan Pharms; Hetero Labs Ltd V; Apotex; Accord Hlthcare; Aurobindo Pharma; Torrent Pharms; Sandoz; Roxane; Glenmark Generics; Teva Pharms; Macleods Pharms; Kudco Ireland; Dr Reddys Labs |
| 2 of 4 | |
|---|---|
| Drug Name | Singulair |
| Drug Label | Montelukast sodium, the active ingredient in SINGULAIRRegistered trademark of MERCK & CO., Inc.COPYRIGHT 1998-2009 MERCK & CO., Inc.All rights reserved, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl |
| Active Ingredient | Montelukast sodium |
| Dosage Form | Tablet; Granule; Tablet, chewable |
| Route | Oral |
| Strength | eq 4mg base; eq 5mg base; eq 4mg base/packet; eq 10mg base |
| Market Status | Prescription |
| Company | Merck |
| 3 of 4 | |
|---|---|
| Drug Name | Montelukast sodium |
| PubMed Health | Montelukast (By mouth) |
| Drug Classes | Anti-Inflammatory |
| Drug Label | Montelukast sodium, the active ingredient in montelukast sodium tablets and montelukast sodium chewable tablets, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT1 receptor.Montelukast sodi... |
| Active Ingredient | Montelukast sodium |
| Dosage Form | Tablet; Granule; Tablet, chewable |
| Route | Oral |
| Strength | eq 4mg base; eq 5mg base; eq 4mg base/packet; eq 10mg base |
| Market Status | Prescription |
| Company | Vintage Pharms; Mylan Pharms; Hetero Labs Ltd V; Apotex; Accord Hlthcare; Aurobindo Pharma; Torrent Pharms; Sandoz; Roxane; Glenmark Generics; Teva Pharms; Macleods Pharms; Kudco Ireland; Dr Reddys Labs |
| 4 of 4 | |
|---|---|
| Drug Name | Singulair |
| Drug Label | Montelukast sodium, the active ingredient in SINGULAIRRegistered trademark of MERCK & CO., Inc.COPYRIGHT 1998-2009 MERCK & CO., Inc.All rights reserved, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl |
| Active Ingredient | Montelukast sodium |
| Dosage Form | Tablet; Granule; Tablet, chewable |
| Route | Oral |
| Strength | eq 4mg base; eq 5mg base; eq 4mg base/packet; eq 10mg base |
| Market Status | Prescription |
| Company | Merck |
Asthma
Anti-Asthmatic Agents
Drugs that are used to treat asthma. (See all compounds classified as Anti-Asthmatic Agents.)
Cytochrome P-450 CYP1A2 Inducers
Drugs and compounds that induce the synthesis of CYTOCHROME P-450 CYP1A2. (See all compounds classified as Cytochrome P-450 CYP1A2 Inducers.)
Leukotriene Antagonists
A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level. (See all compounds classified as Leukotriene Antagonists.)
API SUPPLIERS
Together we can improve the quality of life
Jai Radhe Sales is your partner for all your sourcing needs.
Minakem is manufacturing small molecules APIs including corticosteroids
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16243
Submission : 2002-11-15
Status : Active
Type : II
Inke S.A: APIs manufacturing plant.
Registration Number : 227MF10180
Registrant's Address : Area Industrial del Llobregat, C/Argent 1,08755 Castellbisbal Barcelona SPAIN
Initial Date of Registration : 2015-07-13
Latest Date of Registration :
| Available Reg Filing : ASMF |
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Registrant Name : Toru Corporation
Registration Date : 2021-05-04
Registration Number : 20210504-209-J-753
Manufacturer Name : Metrochem API Private Limited (Unit-I)
Manufacturer Address : Plot No. 62/C/6, Pipeline Road, Phase - I, IDA., Jeedimetla, Quthbullapur Mandal Medchal District - 500 055 Telangana, India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-02-18
Pay. Date : 2012-12-31
DMF Number : 24516
Submission : 2010-12-31
Status : Active
Type : II
Certificate Number : R1-CEP 2012-115 - Rev 03
Issue Date : 2023-07-12
Type : Chemical
Substance Number : 2583
Status : Valid
Registration Number : 307MF10039
Registrant's Address : 8-2-337, Road No. 3,Banjara Hills,Hyderabad 500 034,TELANGANA,INDIA
Initial Date of Registration : 2025-02-26
Latest Date of Registration :
Date of Issue : 2022-05-27
Valid Till : 2025-06-04
Written Confirmation Number : WC-0043
Address of the Firm :
NDC Package Code : 55111-084
Start Marketing Date : 2010-12-31
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Pami Future Co., Ltd.
Registration Date : 2022-06-29
Registration Number : 20220629-209-J-1272
Manufacturer Name : Dr. Reddy's Laboratories Ltd.
Manufacturer Address : Chemical Technical Operations-Unit-Ⅴ, Peddadevulapally Village, Tripuraram Mandal, Nalgonda District, 508 207, Telangana State, India
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
Together we can improve the quality of life
About the Company : Shamrock Pharmachemi Pvt Ltd. is a globally recognized API leader with over 26 years of expertise in human and veterinary pharmaceuticals. Operating in 40+ countries, we own two st...
Jai Radhe Sales is your partner for all your sourcing needs.
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
Inke S.A: APIs manufacturing plant.
About the Company : Inke S.A., is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes for diverse the...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
About the Company : Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, corticosteroids, cyto...
HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
About the Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for critical and high-g...
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
About the Company : Tenatra International was established as a proprietorship firm in 1999. It got off to a very good start, supporting clients in the United States, Mexico and Europe. As business opp...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Montelukast VersaFilm (montelukast) is a leukotriene receptor antagonist, which is being evaluated in patients with Parkinson’s Disease, the second most common neurodegenerative disease.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Brand Name: Montelukast VersaFilm
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 04, 2024
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IntelGenx Doses First Parkinson’s Patients with Montelukast VersaFilm in Phase 2 Trial
Details : Montelukast VersaFilm (montelukast) is a leukotriene receptor antagonist, which is being evaluated in patients with Parkinson’s Disease, the second most common neurodegenerative disease.
Product Name : Montelukast VersaFilm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2024
Details:
Montelukast VersaFilm (montelukast) is a small molecule CysLT1 receptor inhibitor, given in the form of buccal film, is currently being ivestigated for patients with alzheimer's disease.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Brand Name: Montelukast VersaFilm
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 07, 2024
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IntelGenx Reports Preliminary Results for Montelukast VersaFilm® in Alzheimer’s Disease
Details : Montelukast VersaFilm (montelukast) is a small molecule CysLT1 receptor inhibitor, given in the form of buccal film, is currently being ivestigated for patients with alzheimer's disease.
Product Name : Montelukast VersaFilm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 07, 2024
Details:
VersaFilm® (montelukast) is a leukotriene receptor antagonist, which is completed patient enrollment in the ongoing Phase 2a clinical trial in patients with mild to moderate Alzheimer’s Disease.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Brand Name: Montelukast VersaFilm
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 14, 2023
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IntelGenx Receives Approval to Conduct MONTPARK™ Montelukast VersaFilm® Phase 2 Clinical Trial ...
Details : VersaFilm® (montelukast) is a leukotriene receptor antagonist, which is completed patient enrollment in the ongoing Phase 2a clinical trial in patients with mild to moderate Alzheimer’s Disease.
Product Name : Montelukast VersaFilm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 14, 2023
Details:
Upon completion of the Study, IntelGenx will retain the intellectual property rights and use the findings to further develop its Montelukast VersaFilm® program for Parkinson's disease treatment.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Brand Name: Montelukast VersaFilm
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Karolinska Institute
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 02, 2023
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Karolinska Institute
Deal Size : $2.0 million
Deal Type : Collaboration
Details : Upon completion of the Study, IntelGenx will retain the intellectual property rights and use the findings to further develop its Montelukast VersaFilm® program for Parkinson's disease treatment.
Product Name : Montelukast VersaFilm
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 02, 2023
Details:
The agreement aims to investigate the use of IntelGenx’s Montelukast VersaFilm, a leukotriene receptor antagonist, for the treatment of Parkinson’s Disease.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Brand Name: Montelukast VersaFilm
Study Phase: IND EnablingProduct Type: Other Small Molecule
Sponsor: Karolinska University Hospital
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 25, 2023
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Karolinska University Hospital
Deal Size : $2.0 million
Deal Type : Agreement
IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Tre...
Details : The agreement aims to investigate the use of IntelGenx’s Montelukast VersaFilm, a leukotriene receptor antagonist, for the treatment of Parkinson’s Disease.
Product Name : Montelukast VersaFilm
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 25, 2023
Details:
VersaFilm® (montelukast) is a leukotriene receptor antagonist, which is completed patient enrollment in the ongoing Phase 2a clinical trial in patients with mild to moderate Alzheimer’s Disease.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Brand Name: Montelukast VersaFilm
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 08, 2023
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IntelGenx Completes Enrollment for ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in ...
Details : VersaFilm® (montelukast) is a leukotriene receptor antagonist, which is completed patient enrollment in the ongoing Phase 2a clinical trial in patients with mild to moderate Alzheimer’s Disease.
Product Name : Montelukast VersaFilm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 08, 2023
Details:
Resumption of patient dosing in the ongoing Phase 2a (BUENA) clinical trial of Montelukast VersaFilm, a leukotriene receptor antagonist on the basis of Phase 1 study data that reduces the first-pass-effect and has a 52% higher bioavailability.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Brand Name: Montelukast VersaFilm
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 20, 2022
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Dosed in IntelGenx’s Resumed ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical...
Details : Resumption of patient dosing in the ongoing Phase 2a (BUENA) clinical trial of Montelukast VersaFilm, a leukotriene receptor antagonist on the basis of Phase 1 study data that reduces the first-pass-effect and has a 52% higher bioavailability.
Product Name : Montelukast VersaFilm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 20, 2022
Details:
In Phase 1 studies, an oral film formulation of Montelukast is safe and tolerable in healthy subjects, reduces the first-pass-effect and has a 52% higher bioavailability compared to the Montelukast tablet, demonstrating a clear advantage of delivering Montelukast via film.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Brand Name: Montelukast VersaFilm
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 10, 2021
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Patient Screening to Resume in IntelGenx’s ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical...
Details : In Phase 1 studies, an oral film formulation of Montelukast is safe and tolerable in healthy subjects, reduces the first-pass-effect and has a 52% higher bioavailability compared to the Montelukast tablet, demonstrating a clear advantage of delivering Mo...
Product Name : Montelukast VersaFilm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2021
Details:
Data suggest Montelukast may inhibit mental decline, higher doses optimal for clinical trials assessing impact on neurological disease.
Lead Product(s): Montelukast Sodium
Therapeutic Area: Neurology Brand Name: Montelukast VersaFilm
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 11, 2020
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IntelGenx Announces Publication of a Study Evaluating Montelukast’s Effect on Neurological Aging
Details : Data suggest Montelukast may inhibit mental decline, higher doses optimal for clinical trials assessing impact on neurological disease.
Product Name : Montelukast VersaFilm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 11, 2020
Details:
Novateur proposes a simple treatment paradigm using a combination of a leukotriene biosynthesis blocker, Zyflo® controlled release formulation and an inhibitor of the cysteinyl leukotriene 1 receptor, Singulair® to target the hyper-inflammatory response insevere COVID-19.
Lead Product(s): Zileuton,Montelukast Sodium
Therapeutic Area: Infections and Infectious Diseases Brand Name: Zyflo
Study Phase: PreclinicalProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 08, 2020
Lead Product(s) : Zileuton,Montelukast Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novateur Study Points Toward Potential COVID-19 Treatment
Details : Novateur proposes a simple treatment paradigm using a combination of a leukotriene biosynthesis blocker, Zyflo® controlled release formulation and an inhibitor of the cysteinyl leukotriene 1 receptor, Singulair® to target the hyper-inflammatory respons...
Product Name : Zyflo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - EQ 10MG BASE
USFDA APPLICATION NUMBER - 20829
DOSAGE - TABLET, CHEWABLE;ORAL - EQ 4MG BASE
USFDA APPLICATION NUMBER - 20830
DOSAGE - TABLET, CHEWABLE;ORAL - EQ 5MG BASE
USFDA APPLICATION NUMBER - 20830
DOSAGE - GRANULE;ORAL - EQ 4MG BASE/PACKET
USFDA APPLICATION NUMBER - 21409
Related Excipient Companies
Minakem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharm-RX Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Minbiotech
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Alcedo Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ashland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]BASF
Dosage Form : Tablet
Grade : Not Available
Brand Name : Kollicoat Protect
Application : Coating Systems & Additives
Excipient Details : Flexible water soluble instant release coating polymer, especially used for moisture protection
Pharmacopoeia Ref : Excipient based on Kollicoat®...
Technical Specs : Not Available
Ingredient(s) : Polyvinyl Alcohol Graft Polyethylene Glycol Copolymer
Dosage Form : Granule / Pellet
Grade : Not Available
Brand Name : Kollicoat SR 30 D
Application : Taste Masking
Excipient Details : pH-independent sustained release coating for small particles, pellets, granules and tablets. Sprayable polymeric film former. Flexible. Wash resistant.
Pharmacopoeia Ref : Ph. Eur.: Poly(vinyl acetate) ...
Technical Specs : Not Available
Ingredient(s) : Sodium Lauryl Sulfate
Dosage Form : Tablet
Grade : Not Available
Application : Fillers, Diluents & Binders
Pharmacopoeia Ref : Ph. Eur., USP monograph "Copov...
Technical Specs : Not Available
Ingredient(s) : Vinylpyrrolidone-Vinyl Acetate
Dosage Form : Emulsion
Grade : Not Available
Application : Topical
Excipient Details : Self-emulsifying and consistency building, easy-to-use base for dermatological creams
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Sodium Lauryl Sulfate
Dosage Form : Tablet
Grade : Not Available
Application : Granulation
Excipient Details : Wetting agent, reduces disintegration time, Ionic solubilizer, high HLB anionic emulsifier for semi-solids and foams.
Pharmacopoeia Ref : Ph. Eur.: Sodium Laurilsulfate...
Technical Specs : Not Available
Ingredient(s) : Sodium Lauryl Sulfate
Dosage Form : Capsule
Grade : Not Available
Application : Film Formers & Plasticizers
Excipient Details : Plasticizer particularly suitable for tablet coatings. Versatile water or oil miscible solvent in topical formulations.
Dosage Form : Emulsion
Grade : Not Available
Brand Name : Kollisolv PEG 300
Application : Solubilizers
Excipient Details : Liquid plasticizer, solvent for oral and topical applications, hydrophilic fill for solubilization of hydrophilic APIs.
Pharmacopoeia Ref : Ph. Eur., JP, FCC, USP
Technical Specs : Not Available
Ingredient(s) : Polyethylene Glycol 300
Dosage Form : Orodispersible Tablet
Grade : Not Available
Application : Chewable & Orodispersible Aids
Excipient Details : Ludiflash is a ready-to-use orally disintegrating tablet (ODT) solution with superior mouthfeel.
Pharmacopoeia Ref : Ph. Eur., USP, JP: 90 % mannit...
Technical Specs : Not Available
Ingredient(s) : Crospovidone
Dosage Form : Granule / Pellet
Grade : Not Available
Application : Direct Compression
Excipient Details : Ready-to-use direct compression solution for tablets.
Dosage Form : Granule / Pellet
Grade : Not Available
Application : Direct Compression
Excipient Details : Ready-to-use direct compression solution for lozenges, chewables and effervescent tablets.
Pharmacopoeia Ref : Ph. Eur., USP/NF and J.P
Technical Specs : Not Available
Ingredient(s) : Lactose
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Bioplus Life Sciences
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Esteem Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Huzhou Sunflower Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Keval Exports
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nitika Pharmaceutical Specialities
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Silverline Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Coating Systems & Additives
Direct Compression
Disintegrants & Superdisintegrants
Granulation
Taste Masking
Thickeners and Stabilizers
Controlled & Modified Release
Lubricants & Glidants
Chewable & Orodispersible Aids
Topical
Film Formers & Plasticizers
Solubilizers
Co-Processed Excipients
Parenteral
Rheology Modifiers
Emulsifying Agents
Empty Capsules
API Stability Enhancers
Coloring Agents
Vegetarian Capsules
Surfactant & Foaming Agents
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
ABOUT THIS PAGE
88
PharmaCompass offers a list of Montelukast Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Montelukast Sodium manufacturer or Montelukast Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Montelukast Sodium manufacturer or Montelukast Sodium supplier.
PharmaCompass also assists you with knowing the Montelukast Sodium API Price utilized in the formulation of products. Montelukast Sodium API Price is not always fixed or binding as the Montelukast Sodium Price is obtained through a variety of data sources. The Montelukast Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Merck brand of montelukast sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Merck brand of montelukast sodium, including repackagers and relabelers. The FDA regulates Merck brand of montelukast sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Merck brand of montelukast sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Merck brand of montelukast sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Merck brand of montelukast sodium supplier is an individual or a company that provides Merck brand of montelukast sodium active pharmaceutical ingredient (API) or Merck brand of montelukast sodium finished formulations upon request. The Merck brand of montelukast sodium suppliers may include Merck brand of montelukast sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Merck brand of montelukast sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Merck brand of montelukast sodium DMF (Drug Master File) is a document detailing the whole manufacturing process of Merck brand of montelukast sodium active pharmaceutical ingredient (API) in detail. Different forms of Merck brand of montelukast sodium DMFs exist exist since differing nations have different regulations, such as Merck brand of montelukast sodium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Merck brand of montelukast sodium DMF submitted to regulatory agencies in the US is known as a USDMF. Merck brand of montelukast sodium USDMF includes data on Merck brand of montelukast sodium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Merck brand of montelukast sodium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Merck brand of montelukast sodium suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Merck brand of montelukast sodium Drug Master File in Japan (Merck brand of montelukast sodium JDMF) empowers Merck brand of montelukast sodium API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Merck brand of montelukast sodium JDMF during the approval evaluation for pharmaceutical products. At the time of Merck brand of montelukast sodium JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Merck brand of montelukast sodium suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Merck brand of montelukast sodium Drug Master File in Korea (Merck brand of montelukast sodium KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Merck brand of montelukast sodium. The MFDS reviews the Merck brand of montelukast sodium KDMF as part of the drug registration process and uses the information provided in the Merck brand of montelukast sodium KDMF to evaluate the safety and efficacy of the drug.
After submitting a Merck brand of montelukast sodium KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Merck brand of montelukast sodium API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Merck brand of montelukast sodium suppliers with KDMF on PharmaCompass.
A Merck brand of montelukast sodium CEP of the European Pharmacopoeia monograph is often referred to as a Merck brand of montelukast sodium Certificate of Suitability (COS). The purpose of a Merck brand of montelukast sodium CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Merck brand of montelukast sodium EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Merck brand of montelukast sodium to their clients by showing that a Merck brand of montelukast sodium CEP has been issued for it. The manufacturer submits a Merck brand of montelukast sodium CEP (COS) as part of the market authorization procedure, and it takes on the role of a Merck brand of montelukast sodium CEP holder for the record. Additionally, the data presented in the Merck brand of montelukast sodium CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Merck brand of montelukast sodium DMF.
A Merck brand of montelukast sodium CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Merck brand of montelukast sodium CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Merck brand of montelukast sodium suppliers with CEP (COS) on PharmaCompass.
A Merck brand of montelukast sodium written confirmation (Merck brand of montelukast sodium WC) is an official document issued by a regulatory agency to a Merck brand of montelukast sodium manufacturer, verifying that the manufacturing facility of a Merck brand of montelukast sodium active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Merck brand of montelukast sodium APIs or Merck brand of montelukast sodium finished pharmaceutical products to another nation, regulatory agencies frequently require a Merck brand of montelukast sodium WC (written confirmation) as part of the regulatory process.
click here to find a list of Merck brand of montelukast sodium suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Merck brand of montelukast sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Merck brand of montelukast sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Merck brand of montelukast sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Merck brand of montelukast sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Merck brand of montelukast sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Merck brand of montelukast sodium suppliers with NDC on PharmaCompass.
Merck brand of montelukast sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Merck brand of montelukast sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Merck brand of montelukast sodium GMP manufacturer or Merck brand of montelukast sodium GMP API supplier for your needs.
A Merck brand of montelukast sodium CoA (Certificate of Analysis) is a formal document that attests to Merck brand of montelukast sodium's compliance with Merck brand of montelukast sodium specifications and serves as a tool for batch-level quality control.
Merck brand of montelukast sodium CoA mostly includes findings from lab analyses of a specific batch. For each Merck brand of montelukast sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Merck brand of montelukast sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Merck brand of montelukast sodium EP), Merck brand of montelukast sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Merck brand of montelukast sodium USP).
